EGFR-targeting RNase A-cetuximab antibody-drug conjugate induces ROS-mediated apoptosis to overcome drug resistance in KRAS mutant cancer cells

Abstract Antibody-drug conjugates (ADCs) are an emerging strategy in cancer therapy, enhancing precision and efficacy by linking targeted antibodies to potent cytotoxic agents. This study introduces a novel ADC that combines ribonuclease A (RNase A) with cetuximab (Cet), an anti-EGFR monoclonal anti...

Full description

Saved in:
Bibliographic Details
Main Authors: Bita Jafary, Mostafa Akbarzadeh-Khiavi, Hamed Farzi-Khajeh, Azam Safary, Khosro Adibkia
Format: Article
Language:English
Published: Nature Portfolio 2025-01-01
Series:Scientific Reports
Subjects:
Online Access:https://doi.org/10.1038/s41598-025-85856-9
Tags: Add Tag
No Tags, Be the first to tag this record!